David M. Nierengarten

In a report published Monday, Wedbush analysts David M. Nierengarten, Ph.D., and Dilip Joseph previewed fourth quarter earnings for Raptor Pharmaceutical Corp. (NASDAQ: RPTP), “lowering sales estimates with US market saturation and slow EU launch.” The specialists reiterated an...

In a report published Wednesday, Wedbush analyst David M. Nierengarten reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE), and raised the price target from $51.00 to $94.00. In the report, Wedbush noted, “Updated data presented at ASH today shows that the first four beta-thal patients...

In a report published Tuesday, Wedbush analyst David M. Nierengarten initiated coverage on Karyopharm Therapeutics Inc (NASDAQ: KPTI) with an Outperform rating and $50.00 price target. In the report, Wedbush noted, “KPTI's lead product, Selinexor (KPT-330), is a first-in-class oral nuclear export...

In a report published Thursday, Wedbush analyst David M. Nierengarten initiated coverage on MEI Pharma (NASDAQ: MEIP) with an Outperform rating and $12.00 price target. In the report, Wedbush noted, “MEI Pharma is developing pracinostat, a best-in-class oral histone deacetylase inhibitor (HDAC...

In a report published Monday, Wedbush analyst David M. Nierengarten initiated coverage on Fate Therapeutics (NASDAQ: FATE) with an Outperform rating and $14.00 price target. In the report, Wedbush noted, “FATE is developing modified hematopoietic stem cells (HSCs) to improve outcomes in allogeneic...

In a report published Monday, Wedbush analyst David M. Nierengarten downgraded the rating on Synageva BioPharma Corp. (NASDAQ: GEVA) from Outperform to Neutral, but raised the price target from $55.00 to $67.00. In the report, Wedbush noted, “We are downgrading shares of Synageva due to valuation...

In a report published Thursday, Wedbush analyst David M. Nierengarten initiated coverage on Stemline Therapeutics (NASDAQ: STML) with an Outperform rating and $49.00 price target. In the report, Wedbush noted, “Stemline Therapeutics is a biotechnology company that is developing novel oncology...